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From summary and commentary
Deaths were tracked among patients in
Ireland prescribed methadone in primary
care between 2004 and 2010.
Records revealed that patients were nearly
four times more likely to die during periods
out of treatment, and that the first few
weeks after leaving were the peak risk
period.
Implications are that efforts should be
made to encourage retention and that
when patients do leave they should be
monitored over at least the first month.
Findings challenge the recent emphasis in
the UK on curtailing the duration of opioid
substitute prescribing programmes.
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Primary care methadone patients in Ireland were nearly four times more likely to die during periods
out of treatment; the first few weeks after leaving were the peak risk period. The study’s support for
unbroken, long-term treatment runs counter to recent UK government policy.
SUMMARY This study followed up patients prescribed methadone by primary care practices in Ireland
to establish whether death rates vary during treatment phases (initiation and cessation) and whether
features such as dose and methadone being taken under clinical supervision (‘supervised consumption’)
are associated with death rates.
The context is that numbers in methadone maintenance
in Ireland have been increasing, with about a third
treated in primary care, but there has been no
corresponding decrease in deaths from opioid overdose.
Irish guidelines recommend methadone consumption be
supervised at least once a week. Supervised
consumption is believed to prevent deaths by ensuring
patients take their methadone as intended and avoiding
it being ‘diverted’ to other users. Diversion risks
patients being under-treated and relapsing to illicit
heroin use.
Research methods
The featured study was based on cross-referencing
official records kept nationally in Ireland. It focused on
patients prescribed and dispensed methadone in
primary care between 1 August 2004 and the end of
2010 identified in a national register of methadone
maintenance patients. This register was linked to
dispensing records for methadone and all other
medications, and to mortality data recorded in a
national census of drug-related deaths (deaths recorded on the death certificate as directly
attributable to drug use) and deaths among drug users. Patients were followed-up during treatment and
(as long as they remained alive) for up to a year after the expiry of their last methadone prescription
until the end of 2010.
A patient was defined as still being in treatment if they received their next prescription for methadone
within three days of the period covered by their previous prescription, after which UK guidelines say
patients should be reassessed before recommencing treatment. Longer gaps were considered time
spent out of treatment. Typical doses during each patient’s last treatment episode were categorised in
relation to the recommended range of 60–120mg daily. Consumption during a given week was assumed
to have been supervised if a prescription for the dispensing of a single dose was followed no more than
a day later by another for a single dose or for several days. A period of regular supervision was defined
as having over half one’s prescriptions supervised.
The patients
Over the six-year study period 6983 patients aged 16–65 were prescribed and dispensed methadone
and this prescribing was documented sufficiently fully to be included in the analysis. They were followed
up for from about a month to over six years, but typically for about four years and four months. Over
two-thirds were men and most were aged under 30. Multiple treatment episodes were the norm, though
almost 60% of patients had at least one episode lasting a year or more. Almost 60% received doses in
the recommended range; nearly all the rest were prescribed lower doses Four in ten had their
consumption regularly supervised. Nearly three-quarters had also been prescribed benzodiazepines and
nearly half antidepressants.
Main findings
Either during treatment or within a year of leaving, over the six years of the study 213 or 3% of the
patients died. Of these, 78 deaths were identified as due to ‘poisoning’ by drugs, all but a few involving
opiate-type drugs and three-quarters benzodiazepines.
With so few drug-related deaths the analysis did not produce statistically significant findings, though
some of the relationships between the death rate and other factors were substantial. While in
treatment the drug-related death rate was equivalent to 0.24 deaths per 100 patients in treatment for
a year, lower than the 0.39 per 100 while people were out of treatment. Lowest of all was the
equivalent drug-related death rate at the start of treatment – just 0.11 in the first two weeks and 0.13
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equivalent drug-related death rate at the start of treatment – just 0.11 in the first two weeks and 0.13
in the next two, compared to 0.26 during the remaining time in treatment. The death rate peaked in the
weeks after leaving treatment, reaching 0.49 in the first fortnight and 1.19 during the next two weeks.
Compared to other times in or out of treatment, drug-related deaths were proportionately slightly fewer
while patients were not subject to regular supervised consumption. Deaths were also slightly fewer
among patients prescribed less than recommended doses.
The above analysis of the 78 deaths recorded as drug-
related was supplemented by one of all 213 deaths, some of
which were likely to have been be due to drugtaking even if
not recorded as such. With this greater number, some of
the relationships between the death rate and other factors
were not just substantial, but also statistically significant,
so unlikely to have been due to chance variations.
While in treatment the overall death rate was equivalent to
an annual toll of 0.51 deaths per 100 patients – after
adjusting for other factors, nearly four times lower than the
1.57 during periods out of treatment, a statistically
significant difference  chart. Like drug-related deaths,
overall deaths were proportionately fewer – but only slightly
and non-significantly – during the first weeks than later in
treatment, bottoming at a rate of 0.39 during the second fortnight. Also like drug-related deaths, the
overall death rate peaked in the weeks after leaving treatment, reaching 3.46 in the first fortnight and
4.38 during the next two weeks. It then fell to 1.07, still significantly greater than (after adjustments,
over twice as great) the death rate after the first four weeks in treatment. Contrary to drug-related
deaths, compared to other times in or out of treatment, deaths overall were proportionately slightly and
non-significantly fewer while patients were subject to regular supervised consumption. As with drug-
related deaths, dose bore no substantial or significant relationship to the overall death rate, but this
was at its lowest among patients prescribed less than recommended doses.
The analysis for overall deaths was re-run assuming that at least a week’s break rather than three days
indicated a period out of treatment. This made no material difference to the findings.
The authors’ conclusions
Similar to previous studies, during treatment and up to a year after leaving, over a third of deaths
among methadone patients in primary care in Ireland were identified as related to drug use, mainly
involving opiates and benzodiazepines, and deaths were fewer while patients were in treatment and
peaked shortly after leaving.
Unlike previous studies, there was no evidence of an elevated risk of death when starting treatment
compared to later treatment periods, nor that regular supervised consumption prevented deaths. Both
findings may have been due to inadequate sample size or other factors. Patients in this study may have
been transferring between specialist treatment and primary care rather than starting or leaving
treatment as such, perhaps accounting for no treatment-entry spike in deaths, and supervised
consumption may have been enforced due to the patient’s instability, obscuring any restraining
influence on the death rate.
Implications are that efforts should be made to encourage retention in treatment in primary care; up to
a year after leaving, patients are almost four times as likely to die as when in treatment. When patients
do leave, especially over the first month monitoring and follow-up should be considered. Further
research is needed to determine the optimal duration and frequency of supervised consumption. Long-
term supervision of stable patients may prevent them normalising their lives and lead them (see for
example this British randomised trial) to drop out of treatment, even if it also helps prevent illegal drug
use during treatment.
The fact that so many patients were also being prescribed benzodiazepines is a concern; these drugs
may have contributed to over three-quarters of the drug-related deaths. Such prescribing may reflect
a valid need for treatment of anxiety disorders, but may also be a sign of benzodiazepine misuse or of
the maintenance treatment of benzodiazepine dependence.
It is important to remember that studies of this kind can only tease out links between variables, not
establish that these represent cause and effect; the possibility remains that other factors account for
the relationships. However, data linkage studies such as this are an essential means of evaluating the
protective effects of treatment. Compared to controlled studies, they allow for larger samples, longer
follow-up, and detailed prescribing, monitoring and management information over time.
 COMMENTARY This important study adds to evidence that users of heroin or other
opiate-type drugs who are considered suitable for substitute prescribing, and who seek or at least
accept this treatment, are likely to live longer if it is made available than if it is not. Across relevant
studies from around the world, when opioid-dependent adults are in a substitute prescribing programme
they are less than half as likely to die as when not in treatment. The longer patients remain in these
programmes, the greater the life-expectancy dividend. The first few weeks after leaving are especially
fraught as patients relapse to or increase their opiate use while beyond addiction-related medical care.
These conclusions might be challenged if the kind of people with (at least at that time of their lives)
the resources and support which enable them to stick with treatment would in any event have been at
lower risk than less promising patients. That may account for part of the apparent life-saving dividend,
but from other studies (1 2 3 4) we know it is not the whole story; substitute prescribing does have a
real life-saving impact.
Health benefits are one of the main reasons why the World Health Organization has given unequivocal
backing to methadone and other forms of long term maintenance treatments as the prime modality for
treating dependence on heroin and allied drugs, and why in 2005 it recognised methadone and
buprenorphine as “essential medicines”.
As detailed below, the implications of the featured study run counter to the preference among senior
figures in the UK government for methadone prescribing to be short-term, positions held despite
relatively strong evidence of the health and other benefits of extended treatment from a US randomised
trial, and from a UK study very similar to the featured study. Evidence is one part of the decision-
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trial, and from a UK study very similar to the featured study. Evidence is one part of the decision-
making equation, but how strongly that evidence weighs in the balance is a matter of values; as
discussed below, some see more deaths as worth the prospect of more revitalised lives. Both the Irish
and the UK study found a greatly elevated death rate in the weeks after leaving treatment, the
reasons for which are unclear, as is why the Irish study found supervised consumption unrelated to the
death rate. Before addressing those issues in more detail, it is important to acknowledge the main
limitations of the featured study.
Restricted to patients and to primary care
Though relevant to the survival of people in methadone treatment, the featured study does not add to
our knowledge of arguably the more critical question of whether deaths overall of patients and non-
patients are increased or decreased by widespread methadone maintenance programmes. Other reports
have highlighted deaths among non-patients who have obtained methadone on the illicit market.
Whether lives are on balance saved depends (1 2) on achieving the right balance between access and
control, flexibility and regulation. Get this right, and methadone and buprenorphine programmes make
the greatest known contribution to reducing opiate-related deaths. Get this wrong, and deaths due to
diverted medication, among patients unable to access the programme, who continue to use illegal drugs
due to inadequate doses, whose induction on to methadone has not been sufficiently well monitored, or
who have been forced out or deterred by expense, onerous requirements, or unrealistic expectations of
compliance and progress, can all become a concern.
Another important limitation of the featured study is its restriction to primary care. Patients may not
have been typical of the entire Irish caseload in treatment at specialist clinics as well as in primary
care, and they may have entered and left primary care not from/to no treatment, but from/to the same
treatment conducted in another setting. The most likely transition was from specialist clinics to primary
care after patients have been stabilised and dose levels established, possibly accounting for the failure
to find that the normally risky first few weeks of methadone treatment (1 2 3 4) was associated with
an elevated death rate.
Transition from primary care to a specialist clinic seems less likely. Leaving primary care treatment
probably represented leaving treatment altogether, helping explain the greatly elevated death rate. Had
the rate in the first four weeks been extended over a year, it would have meant 4 in every 100 former
patients dying. Whether the deaths were actually caused by leaving treatment cannot be established;
perhaps patients left precisely because their lives had become destabilised, or they wanted to return to
regular injecting of illegally obtained opiates despite the risks. But other studies in which treatment has
been denied or leaving forced on patients (1 2 3 4) suggest that the shield offered by methadone, and
perhaps too the associated frequent medical contact, is an active ingredient in avoiding preventable
deaths.
Another limitation of the study is the one-year post-treatment cut off, making it impossible to establish
whether the post-treatment death rate trended down as former patients developed lives free of both
risky substance use and of addiction treatment.
Corresponding UK study produces results similar to Irish study
A UK study very similar to the featured study also produced similar results. It drew on a large database
of records of about 3.5 million patients attending over 460 general practices. With minor exceptions,
the researchers analysed records of all patients with a diagnosis of substance misuse who had been
prescribed methadone or buprenorphine between 1990 and 2005, tracking their fate through
prescription records until the end of this period or until they left the practice. Patients who left
treatment were tracked until a year after the expiry of their last prescription. Only overall deaths were
analysed, not specifically drug-related deaths.
After adjusting for other factors, the death rate while out of treatment was over twice as high (229%)
as in treatment. Compared to the general population of the same sex and age range, while in treatment
patients were about five times more likely to die, but while out of treatment, nearly 11 times more
likely.
Safest of all was being in treatment after the first four
weeks, when patients have had time to stabilise their lives
and their dose of substitute medication  chart. Most risky
of all was the four weeks after leaving treatment, when the
death rate was 8–9 times higher than after the first four
weeks of treatment. After patients had survived nearly a
month out of treatment, the death rate plummeted, but
remained nearly twice as high as during the ‘stabilised’
treatment period. Unlike the featured study, the death rate
was also elevated during the first four weeks of treatment,
when doctors and patients may have been feeling their way
towards a safe but effective dose, and some patients may
not yet have adjusted to life without heroin.
Treatment durations longer than nine months were
associated with at least a 50-50 chance that treatment
saved lives, rising to a better than 8 in 10 chance after around a year and to virtual certainty after
another four months, a level sustained at least up to nearly two years of treatment.
One in ten methadone treatments but nearly half on buprenorphine ended with a presumed attempt to
ease treatment exit by gradually reducing doses to very low levels, but this made no significant
difference to the excess mortality in the four weeks after leaving treatment.
Fed in to a simulation model for the UK, this data led to the estimate that shortening an average nine-
month treatment episode to six would cause 10% more deaths, while extending it to 12 months would
lead to a 5% decrease.
Implications contrary to UK government policy
The main implication of both studies – the life-preserving importance of unbroken, long-term treatment
– runs directly counter to the attempts of the UK government to gain expert endorsement for setting
time limits to opioid substitute prescribing programmes, among which methadone maintenance
dominates in the UK as in Ireland. In turn this position reflects the longstanding view among some
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dominates in the UK as in Ireland. In turn this position reflects the longstanding view among some
senior figures in the current government that rather than being a treatment for addiction, methadone
maintenance “perpetuates addiction and dependency”.
That view was expressed in July 2007 when in opposition David Cameron’s ‘New’ Conservatives released
the fruits of their addictions policy think tank. A similar view was even more trenchantly expressed in
Conservative Party policy in the run up to the May 2010 election, which saw methadone maintenance
as “drug dependency courtesy of the state”, a view which can be seen as translating into addictions
treatment policy the Conservatives’ determination to reduce dependence on the state in the form of
welfare benefits.
Most prominently, in 2012 the same sentiment featured in the coalition government’s policy document
Putting Full Recovery First, presented as “the Government’s roadmap for building a new treatment
system based on recovery”. Signed by the chair of the Inter-Ministerial Group on Drugs and seemingly
endorsed by major departments of state including the Cabinet Office, the document promised to bring
“an urgent end to the current drift of far too many people into indefinite maintenance, which is a
replacement of one dependency with another”.
Putting Full Recovery First was a precursor to repeated challenges made to expert advisers to consider
and re-consider the evidence for time-limiting methadone prescribing, some of which were recalled in
2013 by Paul Hayes, former head of England’s National Treatment Agency for Substance Misuse:
“There’s still an appetite in bits of government to re-ask the question about time-limited methadone ...
which in my time they asked four times and always got the same answer. They keep hoping they’ll
finally find someone to tell them what they want to hear, but the evidence remains the evidence.”
The latest public challenge came in 2014 when the Government asked its official advisers on drug policy
on the Advisory Council on the Misuse of Drugs “whether the evidence supports the case for time-
limiting opioid substitution therapy”. The resulting rejection was the most explicit to surface from an
official body. Not only did the Council’s report foresee negative health and crime consequences from
time limits or otherwise curtailing prescribing, but it turned the tables by arguing that far from being in
treatment too long, generally patients in England were there too short a time, and that rather than
restricting access to maintenance, access should be widened. In this they echoed the comments of US
recovery ‘guru’ William White for a Scottish report which, as in the UK as a whole, had responded to
government concerns over the role of methadone in recovery: “In the US, there are periodic moral
panics about the idea of patients being on methadone for prolonged periods – an image that obscures
the real problem which is that most patients are not on methadone long enough, eg, high rates of early
drop-out, administrative discharge and rapid resumption of opioid addiction.”
Revealing the depth of opposition to maintenance in some quarters of government, the Advisory
Council’s report drew the ire of Iain Duncan Smith, leader of the Department for Work and Pensions,
who publicly accused advisers appointed by his own government of “providing cover for perpetuating
drug addiction in the UK”.
Drug and Alcohol Findings has traced the recent history of opposition to maintenance in Britain in a hot
topic entry, which dates the current debate back to the mid-2000s and the then Labour government’s
concern to contain costs and free up treatment slots by getting patients to the point where they could
leave treatment, partially reversing the previous emphasis on retention.
Rare randomised trial finds maintenance cost-effective lifesaver
The Effectiveness Bank’s analysis of the Advisory Council’s report recounts the “strong” evidence the
experts found that “time-limiting opioid substitution therapy would increase the rate of overdose
deaths” and have other negative consequences.
Among this corpus, randomised trials have been rare. The most relevant to current British policy was
conducted in the 1990s in the USA. It can be seen as having tested a time-limited methadone
stabilisation programme acting as a preparation for detoxification – the preferred approach among
leading government figures – against something more like extended methadone maintenance. The
implications of its findings have been explored in the Effectiveness Bank’s Drug Treatment Matrix and in
an Effectiveness Bank research analysis. Reports on both the original trial and on a cost-effectiveness
analysis are freely available. As detailed below (unfold supplementary text ), these showed that
compared to post-detoxification patients, patients in the other arm of the trial who were still being
maintained used illicit opiates less often, had fewer legal complications, and were at lower risk of blood-
borne diseases, translating into an estimated low-cost extension of life. Results also clearly showed
methadone’s holding power – both its strength as a treatment and the source of its condemnation.
The researchers’ verdict was pointed: “[no] support for diverting resources from methadone
maintenance to long-term detoxification, no matter how ideologically attractive the notion of a time-
limited treatment for opioid abusers.” For many the bottom-line argument for maintenance would have
been the study’s estimate that relative to detoxification, it will have saved lives. That, however, takes
us into the domain of values – of what matters most. For some informed UK observers the lifesaving
argument is a clincher, but for others, “Leaving the protection of methadone maintenance treatment
may increase the risk of death. But it might also be the way to a brand new life beyond your wildest
dreams, where you find jobs, homes and friends.” The prospect – even the certainty – of more deaths
may not convince those who feel a life tied to a methadone clinic to daily swallow the drug in front of
staff and submit to observed urine tests, yielding control of significant parts of your life, is not the best
of lives. It can be countered that being precipitated back on the streets to fund and obtain illicit heroin
is not much of a life either, and much more dangerous. But a proportion of former patients will swim
rather than sink – and for some on the banks, the sight of those recovered swimmers leaving
methadone and addiction behind is worth the loss of others.
Why was leaving treatment so risky?
In both the Irish and UK studies, the most worrying finding was the greatly elevated death rate
immediately after leaving treatment. The UK study was unable to distinguish between ‘overdose’ deaths
known to have been drug-related versus other deaths, but the featured Irish study could. In that study
the overdose death rate was relatively high in the four weeks after leaving treatment, but these eight
deaths were less than a fifth of all 44 deaths during that period. The implication is that overdoses and
other deaths recognised for the purposes of the death certificate as directly due to drug use were not
the major reason for the spike in deaths after leaving treatment.
Focusing on the overdose deaths, among patients who left treatment after dose reductions one
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Focusing on the overdose deaths, among patients who left treatment after dose reductions one
probable mechanism is clear: like patients exiting detoxification or who stop taking opiate-blocking
medications, they would probably have lost most of their tolerance to opiate-type drugs, leaving them
vulnerable to overdose if (as many would have done) they relapsed to illegal heroin use. But in the UK
study, dose-reduction patients were the minority, and in Ireland, many more deaths were not
attributed to overdose. It seems possible that treatment-leaving is a marker of a dangerous phase in
patients’ lives, perhaps being precipitated by escalating illegal drug use, instability, or a greater
willingness to take risks.
Similar findings have come from Australia, where the death rate in the first two weeks after leaving
(mainly) methadone treatment was found to have been about three times that during the stabilised
treatment period. Overdoses were the main cause of death. An Italian study (analysed by Findings)
found that methadone maintenance patients and former patients were at substantially lower risk of
fatal overdose than patients from other treatment modalities. They remained at lower risk after leaving
treatment, but in this study too, the overdose death rate after leaving methadone maintenance was
much higher than during treatment, probably due to deaths shortly after patients had dropped out. The
researchers commented that in any modality, short treatments might fail to save lives because risks are
concentrated at the start and immediately after the end, and are counterbalanced by the time in
between.
Contrary to these studies, no post-treatment rise in the death rate was recorded in Amsterdam.
Possibly this was because most opiate users there do not inject, so overdose death rates were low
overall, and/or because the definition of when treatment ended excluded the first three days, and
might also have left patients with some prescribed methadone still to take.
Why no link with supervised consumption?
Regular supervised consumption was not associated with fewer deaths in the featured study – all the
more remarkable because the comparison was not between periods during treatment when consumption
was supervised versus not supervised, but between treatment featuring regular supervision and other
periods both in and out of treatment. The effect would have been to load on to the non-supervised
periods the risks of being out of treatment altogether, yet still supervision was not associated with a
reduced death rate.
It seems possible that supervision was imposed at particularly risky periods or on patients not complying
with treatment, and that this counterbalanced any restraining effect of supervision on their risks of
dying. Also it remains possible that supervision saved the lives of people other than the patients on
which the study focused. An important reason for supervising consumption is to prevent methadone
being sold on the illicit market or otherwise ‘diverted’ to people other than the patient for whom it was
intended, with possibly fatal consequences in the form of opioid overdose.
A study of methadone overdoses in Scotland and England suggests these concerns are valid and that
supervision does have the desired impact. It concluded that declines between 1995 and 2004 in the
rate of methadone overdose deaths per dose of prescribed methadone were due to the spread of
supervised consumption. However, this study was unable to determine whether each opiate user in or
out of treatment had become more or less likely to avoid overdose on opiate-type drugs as a whole –
heroin as well as methadone – as a result of the introduction of supervised consumption.
Thanks for their comments on this entry in draft to research author Gráinne Cousins of the School of Pharmacy at the
Royal College of Surgeons in Ireland, Dublin, Ireland. Commentators bear no responsibility for the text including the
interpretations and any remaining errors.
Last revised 18 January 2016. First uploaded 09 January 2016
 Comment/query to editor
 Give us your feedback on the site (two-minute survey)
 Open Effectiveness Bank home page
 Add your name to the mailing list to be alerted to new studies and other site updates
Top 10 most closely related documents on this site. For more try a subject or free text search
STUDY 2010 Risk of death during and after opiate substitution treatment in primary care: prospective observational
study in UK
REVIEW 2014 A review of buprenorphine diversion and misuse: the current evidence base and experiences from around
the world
DOCUMENT 2011 Buprenorphine/naloxone for opioid dependence: clinical practice guideline
STUDY 2012 Randomized trial of standard methadone treatment compared to initiating methadone without counseling:
12-month findings
REVIEW 2014 Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
STUDY 2010 Naltrexone implants compared to methadone: outcomes six months after prison release
STUDY 2010 Were the changes to Sweden’s maintenance treatment policy 2000–06 related to changes in opiate-related
mortality and morbidity?
STUDY 2009 The Drug Treatment Outcomes Research Study (DTORS): final outcomes report
STUDY 2012 A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in
patients on opiate maintenance treatment
DOCUMENT 2014 Time limiting opioid substitution therapy
converted by Web2PDFConvert.com
